HARVARD BIOSCIENCE INC Revenue Disclosure
|
3. |
Revenues |
The following table represents a disaggregation of revenue from contracts with customers for the years ended December 31, 2025, and 2024.
Revenues by type were as follows:
|
Year Ended December 31, |
||||||||
|
(in thousands) |
2025 |
2024 |
||||||
|
Instruments, equipment, software and accessories |
$ | 78,260 | $ | 86,964 | ||||
|
Service, maintenance and warranty contracts |
8,290 | 7,171 | ||||||
|
Total revenues |
$ | 86,550 | $ | 94,135 | ||||
Revenues recognition timing was as follows:
|
Year Ended December 31, |
||||||||
|
(in thousands) |
2025 |
2024 |
||||||
|
Goods and services transferred at a point in time |
$ | 82,339 | $ | 90,420 | ||||
|
Goods and services transferred over time |
4,211 | 3,715 | ||||||
|
Total revenues |
$ | 86,550 | $ | 94,135 | ||||
Revenues by geographic destination were as follows:
|
Year Ended December 31, |
||||||||
|
(in thousands) |
2025 |
2024 |
||||||
|
Americas |
||||||||
|
United States |
$ | 38,966 | $ | 41,738 | ||||
|
Americas - Other |
3,227 | 3,596 | ||||||
|
Europe, Middle East and Africa |
26,710 | 28,405 | ||||||
|
Asia |
||||||||
|
China |
10,969 | 13,297 | ||||||
|
Asia - Other |
6,678 | 7,099 | ||||||
| $ | 86,550 | $ | 94,135 | |||||
Contract Liabilities
The following table provides a summary of contract liabilities as of the periods indicated:
|
December 31, |
||||||||||||||||
|
(in thousands) |
2025 |
2024 |
Change |
Percentage |
||||||||||||
|
Deferred revenue |
||||||||||||||||
|
Service, maintenance and warranty contracts |
$ | 1,934 | $ | 1,560 | $ | 374 | 24 | % | ||||||||
|
Installation and training |
711 | 806 | (95 | ) | -12 | % | ||||||||||
|
Customer advances |
802 | 1,440 | (638 | ) | -44 | % | ||||||||||
|
Total short-term contract liabilities |
3,447 | 3,806 | (359 | ) | -9 | % | ||||||||||
|
Long-term service, maintenance and warranty contracts |
198 | - | 198 | 100 | % | |||||||||||
|
Total contract liabilities |
$ | 3,645 | $ | 3,806 | $ | (161 | ) | -4 | % | |||||||
The following table represents the Company's remaining performance obligations from contracts that are recognized over time as of December 31, 2025:
|
Remaining Performance Obligations |
||||||||||||||||||||||||||||
|
(in thousands) |
|
|
|
|
|
Total |
||||||||||||||||||||||
|
Service, maintenance and warranty contracts |
$ | 1,900 | $ | 183 | $ | 34 | $ | 13 | $ | 2 | $ | - | $ | 2,132 | ||||||||||||||
Changes in the Company’s contract liabilities are primarily due to the timing of receipt of payments under service, maintenance and warranty contracts and lower revenue volumes. During the years ended December 31, 2025, and 2024, the Company recognized revenue of $3.4 million and $3.4 million from contract liabilities that existed at December 31, 2024 and 2023, respectively.
Provision for Expected Credit Losses on Receivables
|
Year Ended December 31, |
||||||||
|
(in thousands) |
2025 |
2024 |
||||||
|
Balance, beginning of period |
$ | 215 | $ | 160 | ||||
|
Provision for expected credit losses |
16 | 60 | ||||||
|
Charge-offs and other |
(24 | ) | (5 | ) | ||||
|
Balance, end of period |
$ | 207 | $ | 215 | ||||
Concentrations
No customer accounted for more than 10% of revenue for the years ended December 31, 2025, and 2024, or for more than 10% of net accounts receivable at December 31, 2025 and 2024.
Warranties
Warranty activity was as follows:
|
Year Ended December 31, |
||||||||
|
(in thousands) |
2025 |
2024 |
||||||
|
Balance, beginning of period |
$ | 318 | $ | 336 | ||||
|
Provision for warranties |
106 | 317 | ||||||
|
Warranty claims |
(210 | ) | (335 | ) | ||||
|
Balance, end of period |
$ | 214 | $ | 318 | ||||
Want the next HARVARD BIOSCIENCE INC revenue disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment HARVARD BIOSCIENCE INC's next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 13, 2026 | Showing above |
| 2024 | Mar 14, 2025 | |
| 2023 | Mar 7, 2024 | |
| 2022 | Mar 9, 2023 | |
| 2021 | Mar 11, 2022 | |
| 2020 | Mar 12, 2021 | |
| 2019 | Mar 16, 2020 | |
| 2018 | Mar 18, 2019 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.